Forty Years Since the Structural Elucidation of Platelet-Activating Factor (PAF): Historical, Current, and Future Research Perspectives

In the late 1960s, Barbaro and Zvaifler described a substance that caused antigen induced histamine release from rabbit platelets producing antibodies in passive cutaneous anaphylaxis. Henson described a ‘soluble factor’ released from leukocytes that induced vasoactive amine release in platelets. Later observations by Siraganuan and Osler observed the existence of a diluted substance that had the capacity to cause platelet activation. In 1972, the term platelet-activating factor (PAF) was coined by Benveniste, Henson, and Cochrane. The structure of PAF was later elucidated by Demopoulos, Pinckard, and Hanahan in 1979. These studies introduced the research world to PAF, which is now recognised as a potent phospholipid mediator. Since its introduction to the literature, research on PAF has grown due to interest in its vital cell signalling functions and more sinisterly its role as a pro-inflammatory molecule in several chronic diseases including cardiovascular disease and cancer. As it is forty years since the structural elucidation of PAF, the aim of this review is to provide a historical account of the discovery of PAF and to provide a general overview of current and future perspectives on PAF research in physiology and pathophysiology.

[1]  A. Schoenenberger,et al.  Analysis of fragmented oxidized phosphatidylcholines in human plasma using mass spectrometry: Comparison with immune assays. , 2019, Free radical biology & medicine.

[2]  B. Beutler,et al.  Platelet-activating factor (PAF) mediates NLRP3-NEK7 inflammasome induction independently of PAFR , 2019, The Journal of experimental medicine.

[3]  Aaron M. Walsh,et al.  Caprine milk fermentation enhances the antithrombotic properties of cheese polar lipids , 2019, Journal of Functional Foods.

[4]  A. Pitt,et al.  A Targeted Mass Spectrometry Approach to detect and quantify Oxidised Phospholipids in plasma samples of Diabetic patients , 2019 .

[5]  I. Zabetakis,et al.  Bioprospecting for Antithrombotic Polar Lipids from Salmon, Herring, and Boarfish By-Products , 2019, Foods.

[6]  J. Mullol,et al.  Platelet-Activating Factor (PAF) in Allergic Rhinitis: Clinical and Therapeutic Implications , 2019, Journal of clinical medicine.

[7]  Ying Jin,et al.  Novel Insights Into the NLRP3 Inflammasome in Atherosclerosis , 2019, Journal of the American Heart Association.

[8]  J. Travers Platelet-Activating Factor as an Effector for Environmental Stressors. , 2019, Handbook of experimental pharmacology.

[9]  I. Zabetakis,et al.  Total, Neutral, and Polar Lipids of Brewing Ingredients, By-Products and Beer: Evaluation of Antithrombotic Activities , 2019, Foods.

[10]  P. Foster,et al.  Platelet activating factor receptor regulates colitis-induced pulmonary inflammation through the NLRP3 inflammasome , 2019, Mucosal Immunology.

[11]  E. Fragopoulou,et al.  Consumption of plant extract supplement reduces platelet activating factor-induced platelet aggregation and increases platelet activating factor catabolism: a randomised, double-blind and placebo-controlled trial , 2019, British Journal of Nutrition.

[12]  I. Zabetakis,et al.  The in vitro antithrombotic properties of ale, lager, and stout beers , 2019, Food Bioscience.

[13]  Aaron M. Walsh,et al.  The effect of ovine milk fermentation on the antithrombotic properties of polar lipids , 2019, Journal of Functional Foods.

[14]  F. Parveen,et al.  An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases , 2019, International journal of molecular sciences.

[15]  Andrés J. García,et al.  TNFα promotes mucosal wound repair through enhanced Platelet Activating Factor Receptor signaling in the epithelium , 2019, Mucosal Immunology.

[16]  John O. Marentette,et al.  Cigarette smoking promotes bladder cancer via increased platelet‐activating factor , 2019, Physiological reports.

[17]  R. Stevens,et al.  Emerging structural biology of lipid G protein‐coupled receptors , 2019, Protein science : a publication of the Protein Society.

[18]  I. Zabetakis,et al.  The Impact of Nutrition and Statins on Cardiovascular Diseases , 2019, Journal of Nutrition Education and Behavior.

[19]  I. Zabetakis,et al.  The Potential Role of Dietary Platelet-Activating Factor Inhibitors in Cancer Prevention and Treatment. , 2019, Advances in nutrition.

[20]  D. Goodenowe,et al.  Plasmalogen deficiency and neuropathology in Alzheimer's disease: Causation or coincidence? , 2019, Alzheimer's & dementia.

[21]  Constantina Nasopoulou,et al.  In Vitro Antithrombotic Properties of Salmon (Salmo salar) Phospholipids in a Novel Food-Grade Extract , 2019, Marine drugs.

[22]  A. Tierney,et al.  Diet and Cardiovascular Disease: The Mediterranean Diet , 2019, The Impact of Nutrition and Statins on Cardiovascular Diseases.

[23]  Constantina Nasopoulou,et al.  The Anti-inflammatory Properties of Food Polar Lipids , 2019, Bioactive Molecules in Food.

[24]  Hui Zhang,et al.  Structural basis for ligand recognition of the human thromboxane A2 receptor , 2018, Nature Chemical Biology.

[25]  S. Nolan,et al.  In vitro Anti‐atherogenic Properties of N‐Heterocyclic Carbene Aurate(I) Compounds , 2018, ChemMedChem.

[26]  Constantina Nasopoulou,et al.  Phospholipids of goat and sheep origin: Structural and functional studies , 2018, Small Ruminant Research.

[27]  Wenjing Zhang,et al.  Amelioration of atherosclerosis in apolipoprotein E-deficient mice by combined RNA interference of lipoprotein-associated phospholipase A2 and YKL-40 , 2018, PloS one.

[28]  Alex C. Bissember,et al.  Progress in the Development of Platelet‐Activating Factor Receptor (PAFr) Antagonists and Applications in the Treatment of Inflammatory Diseases , 2018, ChemMedChem.

[29]  Hualiang Jiang,et al.  Structural basis for signal recognition and transduction by platelet-activating-factor receptor , 2018, Nature Structural & Molecular Biology.

[30]  Constantina Nasopoulou,et al.  Structural Elucidation of Irish Organic Farmed Salmon (Salmo salar) Polar Lipids with Antithrombotic Activities , 2018, Marine drugs.

[31]  I. Zabetakis,et al.  Inflammation, not Cholesterol, Is a Cause of Chronic Disease , 2018, Nutrients.

[32]  E. Brǎiloiu,et al.  Effects of Platelet-Activating Factor on Brain Microvascular Endothelial Cells , 2018, Neuroscience.

[33]  J. McHowat,et al.  PAF Expression in Skin Tumors of Smokers and Never Smokers: a Potential Role in Skin Cancer Development , 2018 .

[34]  Robert P. Lennon,et al.  State of the Heart: An Overview of the Disease Burden of Cardiovascular Disease from an Epidemiologic Perspective. , 2018, Primary care.

[35]  J. Broach,et al.  A Possible Role for Platelet-Activating Factor Receptor in Amyotrophic Lateral Sclerosis Treatment , 2018, Front. Neurol..

[36]  S. Jancar,et al.  Platelet-Activating Factor Receptor Ligands Protect Tumor Cells from Radiation-Induced Cell Death , 2018, Front. Oncol..

[37]  A. Kadioglu,et al.  E-cigarette vapour enhances pneumococcal adherence to airway epithelial cells , 2018, European Respiratory Journal.

[38]  B. Payrastre,et al.  The importance of blood platelet lipid signaling in thrombosis and in sepsis. , 2017, Advances in biological regulation.

[39]  I. Zabetakis,et al.  Phospholipids of Animal and Marine Origin: Structure, Function, and Anti-Inflammatory Properties , 2017, Molecules.

[40]  P. Erne,et al.  Pleiotropic effects of oxidized phospholipids. , 2017, Free radical biology & medicine.

[41]  I. Zabetakis,et al.  Invited review: The anti-inflammatory properties of dairy lipids. , 2017, Journal of dairy science.

[42]  E. Fragopoulou,et al.  Postprandial effects of wine consumption on Platelet Activating Factor metabolic enzymes. , 2017, Prostaglandins & other lipid mediators.

[43]  A new player in interstitial cystitis/bladder pain syndrome: platelet‐activating factor – PAF and its connection to smoking , 2017, Physiological reports.

[44]  E. Walters,et al.  Temporal upregulation of host surface receptors provides a window of opportunity for bacterial adhesion and disease. , 2017, Microbiology.

[45]  E. Tsilibary,et al.  A Review on Platelet Activating Factor Inhibitors: Could a New Class of Potent Metal-Based Anti-Inflammatory Drugs Induce Anticancer Properties? , 2017, Bioinorganic chemistry and applications.

[46]  T. Abe,et al.  Relief from neuropathic pain by blocking of the platelet-activating factor–pain loop , 2017, The FASEB Journal.

[47]  J. Nolan,et al.  Phospholipid oxidation and carotenoid supplementation in Alzheimer’s disease patients , 2017, Free radical biology & medicine.

[48]  Treesa P. Varghese,et al.  Platelet activating factor: A potential biomarker in acute coronary syndrome? , 2017, Cardiovascular therapeutics.

[49]  X. Yin,et al.  Loss of PAFR prevents neuroinflammation and brain dysfunction after traumatic brain injury , 2017, Scientific Reports.

[50]  M. Dermiki,et al.  Evaluation of sensory and in vitro anti-thrombotic properties of traditional Greek yogurts derived from different types of milk , 2017, Heliyon.

[51]  R. Chammas,et al.  Platelet-activating factor (PAF) receptor as a promising target for cancer cell repopulation after radiotherapy , 2017, Oncogenesis.

[52]  L. Shields,et al.  Current Understanding of Platelet-Activating Factor Signaling in Central Nervous System Diseases , 2017, Molecular Neurobiology.

[53]  E. Walters,et al.  Does upregulated host cell receptor expression provide a link between bacterial adhesion and chronic respiratory disease? , 2016, Journal of Translational Medicine.

[54]  D. Ford,et al.  Platelet-Activating Factor Quantification Using Reversed Phase Liquid Chromatography and Selected Reaction Monitoring in Negative Ion Mode , 2016, Lipids.

[55]  M. Lahiri,et al.  Platelet activating factor leads to initiation and promotion of breast cancer , 2016 .

[56]  H. Chap Forty five years with membrane phospholipids, phospholipases and lipid mediators: A historical perspective. , 2016, Biochimie.

[57]  M. Philippova,et al.  Hormetic and anti-inflammatory properties of oxidized phospholipids. , 2016, Molecular aspects of medicine.

[58]  E. Walters,et al.  Platelet‐activating factor receptor (PAFr) is upregulated in small airways and alveoli of smokers and COPD patients , 2016, Respirology.

[59]  A. Salajegheh Angiogenesis in Health, Disease and Malignancy , 2016, Springer International Publishing.

[60]  J. Travers,et al.  Radiation therapy generates platelet-activating factor agonists , 2016, Oncotarget.

[61]  M. Xanthopoulou,et al.  Wine consumption reduced postprandial platelet sensitivity against platelet activating factor in healthy men , 2016, European Journal of Nutrition.

[62]  A. Dziekońska,et al.  Effects of the platelet-activating factor (PAF) on selected quality parameters of cryopreserved bull semen (AI) with reduced sperm motility. , 2016, Polish journal of veterinary sciences.

[63]  M. J. Bellizzi,et al.  Platelet-Activating Factor Receptors Mediate Excitatory Postsynaptic Hippocampal Injury in Experimental Autoimmune Encephalomyelitis , 2016, The Journal of Neuroscience.

[64]  S. Mallik,et al.  Biomarkers and Targeted Therapy in Pancreatic Cancer , 2016, Biomarkers in cancer.

[65]  D. Gozal,et al.  Attenuated Reactive Gliosis and Enhanced Functional Recovery Following Spinal Cord Injury in Null Mutant Mice of Platelet-Activating Factor Receptor , 2015, Molecular Neurobiology.

[66]  Emerging Trends in Retrograde Signaling , 2016, Molecular Neurobiology.

[67]  K. Pałgan,et al.  Platelet activating factor in allergies , 2015, International journal of immunopathology and pharmacology.

[68]  D. Badyal,et al.  Levocetirizine and rupatadine in chronic idiopathic urticaria , 2015, International journal of dermatology.

[69]  M. Lazanas,et al.  The Role of Platelet-Activating Factor in Chronic Inflammation, Immune Activation, and Comorbidities Associated with HIV Infection. , 2015, AIDS reviews.

[70]  Alexandre P. Blanchard,et al.  Platelet activating factors are associated with depressive symptoms in coronary artery disease patients: a hypothesis-generating study , 2015, Neuropsychiatric disease and treatment.

[71]  Tracy E. Macaulay,et al.  Platelet Activating Factor , 2015 .

[72]  S. Watson,et al.  The role of platelets in the recruitment of leukocytes during vascular disease , 2015, Platelets.

[73]  T. Isah Rethinking Ginkgo biloba L.: Medicinal uses and conservation , 2015, Pharmacognosy reviews.

[74]  R. Korstanje,et al.  The role of platelet-activating factor in mesangial pathophysiology. , 2015, The American journal of pathology.

[75]  K. Uzawa,et al.  Lysophosphatidylcholine Acyltransferase1 Overexpression Promotes Oral Squamous Cell Carcinoma Progression via Enhanced Biosynthesis of Platelet-Activating Factor , 2015, PloS one.

[76]  Alun Williams,et al.  α-Synuclein-Induced Synapse Damage in Cultured Neurons Is Mediated by Cholesterol-Sensitive Activation of Cytoplasmic Phospholipase A2 , 2015, Biomolecules.

[77]  J. Bousquet,et al.  Update on rupatadine in the management of allergic disorders , 2015, Allergy.

[78]  Smaragdi Antonopoulou,et al.  Mediterranean Diet and Its Protective Mechanisms against Cardiovascular Disease: An Insight into Platelet Activating Factor (PAF) and Diet Interplay , 2015 .

[79]  John O. Marentette,et al.  Enhanced breast cancer cell adherence to the lung endothelium via PAF acetylhydrolase inhibition: a potential mechanism for enhanced metastasis in smokers. , 2014, American journal of physiology. Cell physiology.

[80]  G. Zimmerman,et al.  Unraveling the PAF-AH/Lp-PLA2 controversy1 , 2014, Journal of Lipid Research.

[81]  G. Marathe,et al.  To hydrolyze or not to hydrolyze: the dilemma of platelet-activating factor acetylhydrolase , 2014, Journal of Lipid Research.

[82]  Takao Shimizu,et al.  Selective inhibitors of a PAF biosynthetic enzyme lysophosphatidylcholine acyltransferase 2[S] , 2014, Journal of Lipid Research.

[83]  J. Travers,et al.  Systemic Platelet-activating Factor Receptor Activation Augments Experimental Lung Tumor Growth and Metastasis , 2014, Cancer growth and metastasis.

[84]  W. Jiang,et al.  The expression of platelet-activating factor receptor modulates the cisplatin sensitivity of ovarian cancer cells: a novel target for combination therapy , 2014, British Journal of Cancer.

[85]  P. Pais,et al.  Darapladib for preventing ischemic events in stable coronary heart disease. , 2014, The New England journal of medicine.

[86]  Y. Uezono,et al.  Palliation of Bone Cancer Pain by Antagonists of Platelet-Activating Factor Receptors , 2014, PloS one.

[87]  A. Yamashita,et al.  Acyltransferases and transacylases that determine the fatty acid composition of glycerolipids and the metabolism of bioactive lipid mediators in mammalian cells and model organisms. , 2014, Progress in lipid research.

[88]  Y. Uezono,et al.  Pain‐releasing action of Platelet‐activating factor (PAF) antagonists in neuropathic pain animal models and the mechanisms of action , 2013, European journal of pain.

[89]  Takao Shimizu,et al.  Generation of membrane diversity by lysophospholipid acyltransferases. , 2013, Journal of biochemistry.

[90]  A. Philippopoulos,et al.  Synthesis, biochemical evaluation and molecular modeling studies of novel rhodium complexes with nanomolar activity against Platelet Activating Factor. , 2013, Journal of inorganic biochemistry.

[91]  T. Nomikos,et al.  Platelet Activating Factor in Heart Failure: Potential Role in Disease Progression and Novel Target for Therapy , 2013, Current Heart Failure Reports.

[92]  A. Tsoupras,et al.  Paricalcitol Effects on Activities and Metabolism of Platelet Activating Factor and on Inflammatory Cytokines in Hemodialysis Patients , 2013, The International journal of artificial organs.

[93]  G. Liss,et al.  Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis. , 2008, The Journal of allergy and clinical immunology.

[94]  R. G. Salomon Structural Identification and Cardiovascular Activities of Oxidized Phospholipids , 2012, Circulation research.

[95]  R. Rosenson,et al.  Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2 , 2012, Journal of Lipid Research.

[96]  M. Lazanas,et al.  Effects of HAART on platelet-activating factor metabolism in naive HIV-infected patients I: study of the tenofovir-DF/emtricitabine/efavirenz HAART regimen. , 2012, AIDS research and human retroviruses.

[97]  J. Grigg The platelet activating factor receptor: a new anti-infective target in respiratory disease? , 2012, Thorax.

[98]  M. Lazanas,et al.  Platelet-Activating Factor and Its Basic Metabolic Enzymes in Blood of Naive HIV-Infected Patients , 2012, Angiology.

[99]  R. Wood‐Baker,et al.  Cigarette smoke and platelet-activating factor receptor dependent adhesion of Streptococcus pneumoniae to lower airway cells , 2012, Thorax.

[100]  R. Chammas,et al.  Expression of PAFR as Part of a Prosurvival Response to Chemotherapy: A Novel Target for Combination Therapy in Melanoma , 2012, Mediators of inflammation.

[101]  D. Panagiotakos,et al.  Mediterranean wild plants reduce postprandial platelet aggregation in patients with metabolic syndrome. , 2012, Metabolism: clinical and experimental.

[102]  Karen Y. Stokes,et al.  Platelets: a critical link between inflammation and microvascular dysfunction , 2012, The Journal of physiology.

[103]  J. Travers,et al.  Loss of the platelet activating factor receptor in mice augments PMA-induced inflammation and cutaneous chemical carcinogenesis. , 2012, Carcinogenesis.

[104]  M. Lazanas,et al.  Effects of Highly Active Antiretroviral Therapy on Platelet Activating Factor Metabolism in Naïve HIV-Infected Patients: II) Study of the Abacavir/Lamivudine/Efavirenz Haart Regimen , 2012, International journal of immunopathology and pharmacology.

[105]  F. Gómez,et al.  Platelet-Activating Factor Antagonists , 2000, BioDrugs.

[106]  Constantina Nasopoulou,et al.  Fish polar lipids retard atherosclerosis in rabbits by down-regulating PAF biosynthesis and up-regulating PAF catabolism , 2011, Lipids in Health and Disease.

[107]  H. Tozaki-Saitoh,et al.  Platelet-activating factor and pain. , 2011, Biological & pharmaceutical bulletin.

[108]  A. Tsoupras,et al.  In Vitro and In Vivo Effects of Statins on Platelet-Activating Factor and Its Metabolism , 2011, Angiology.

[109]  V. Ingham,et al.  Inhibition of phospholipase A2 increased the removal of the prion derived peptide PrP82-146 from cultured neurons , 2011, Neuropharmacology.

[110]  F. Cunha,et al.  Role of platelet-activating factor in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice , 2011, Cancer Chemotherapy and Pharmacology.

[111]  D. Iliopoulos,et al.  Atherosclerosis regression study in rabbits upon olive pomace polar lipid extract administration. , 2010, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[112]  Qiaofang Yi,et al.  Ultraviolet B Radiation of Human Skin Generates Platelet‐activating Factor Receptor Agonists , 2010, Photochemistry and photobiology.

[113]  A. Weyrich,et al.  The platelet activating factor (PAF) signaling cascade in systemic inflammatory responses. , 2010, Biochimie.

[114]  D. Iliopoulos,et al.  In vivo anti-atherogenic properties of cultured gilthead sea bream (Sparus aurata) polar lipid extracts in hypercholesterolaemic rabbits. , 2010 .

[115]  Takao Shimizu,et al.  Role of PAF Receptor in Proinflammatory Cytokine Expression in the Dorsal Root Ganglion and Tactile Allodynia in a Rodent Model of Neuropathic Pain , 2010, PloS one.

[116]  V. Bochkov,et al.  Generation and biological activities of oxidized phospholipids. , 2010, Antioxidants & redox signaling.

[117]  Alun Williams,et al.  Phospholipase A2 inhibitors protect against prion and Aβ mediated synapse degeneration , 2010, Molecular Neurodegeneration.

[118]  S. Nonogaki,et al.  Platelet-activating factor receptor (PAF-R)-dependent pathways control tumour growth and tumour response to chemotherapy , 2010, BMC Cancer.

[119]  A. Tsoupras,et al.  The implication of platelet activating factor in cancer growth and metastasis: potent beneficial role of PAF-inhibitors and antioxidants. , 2009, Infectious disorders drug targets.

[120]  M. Bar‐eli,et al.  Inflammation and melanoma metastasis , 2009, Pigment cell & melanoma research.

[121]  X. Chen,et al.  Platelet Activation by Low Concentrations of Intact Oxidized LDL Particles Involves the PAF Receptor , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[122]  K. Birukov,et al.  Oxidized phospholipids in control of inflammation and endothelial barrier , 2009, Translational Research.

[123]  D. Panagiotakos,et al.  Platelet activating factor (PAF) and activity of its biosynthetic and catabolic enzymes in blood and leukocytes of male patients with newly diagnosed heart failure. , 2009, Clinical biochemistry.

[124]  D. Stafforini Biology of Platelet-activating Factor Acetylhydrolase (PAF-AH, Lipoprotein Associated Phospholipase A2) , 2009, Cardiovascular Drugs and Therapy.

[125]  Frits Mastik,et al.  Effects of the Direct Lipoprotein-Associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque , 2008, Circulation.

[126]  M. Lazanas,et al.  Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection? , 2008, AIDS research and human retroviruses.

[127]  G. Panayotou,et al.  BIOACTIVE POLAR LIPIDS IN OLIVE OIL, POMACE AND WASTE BYPRODUCTS , 2008 .

[128]  M. Hanefeld,et al.  The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. , 2008, Journal of the American College of Cardiology.

[129]  J. Bousquet,et al.  Rupatadine in allergic rhinitis and chronic urticaria , 2008, Allergy.

[130]  D. Loutradis,et al.  Intravenous infusion of PAF affects ovulation, fertilization and preimplantation embryonic development in NZB x NZW F1 hybrid mice. , 2008, Prostaglandins & other lipid mediators.

[131]  M. Bar‐eli,et al.  Emerging Roles of PAR-1 and PAFR in Melanoma Metastasis , 2008, Cancer Microenvironment.

[132]  A. Oliver,et al.  Novel phosphorylcholine-containing protein of Pseudomonas aeruginosa chronic infection isolates interacts with airway epithelial cells. , 2008, The Journal of infectious diseases.

[133]  B. Rogala,et al.  Platelet-activating factor (PAF): a review of its role in asthma and clinical efficacy of PAF antagonists in the disease therapy. , 2008, Recent patents on inflammation & allergy drug discovery.

[134]  B. Rogala,et al.  Platelet Activating Factor as a Mediator and Therapeutic Approach in Bronchial Asthma , 2008, Inflammation.

[135]  Alun Williams,et al.  Ginkgolides protect against amyloid-β1–42-mediated synapse damage in vitro , 2008, Molecular Neurodegeneration.

[136]  M. Bar‐eli,et al.  Inflammation and melanoma growth and metastasis: The role of platelet-activating factor (PAF) and its receptor , 2007, Cancer and Metastasis Reviews.

[137]  D. Iliopoulos,et al.  Antithrombotic and Antiatherosclerotic Properties of Olive Oil and Olive Pomace Polar Extracts in Rabbits , 2007, Mediators of inflammation.

[138]  A. Hermetter,et al.  Oxidized phospholipids: from molecular properties to disease. , 2007, Biochimica et biophysica acta.

[139]  T. Nomikos,et al.  Characterization of the De Novo Biosynthetic Enzyme of Platelet Activating Factor, DDT-Insensitive Cholinephosphotransferase, of Human Mesangial Cells , 2007, Mediators of inflammation.

[140]  V. Bochkov Inflammatory profile of oxidized phospholipids , 2007, Thrombosis and Haemostasis.

[141]  A. Mourelatos,et al.  Effect of traditional Greek Mediterranean meals on platelet aggregation in normal subjects and in patients with type 2 diabetes mellitus. , 2006, Journal of medicinal food.

[142]  F. Labrousse,et al.  Platelet-activating factor in cirrhotic liver and hepatocellular carcinoma. , 2006, World journal of gastroenterology.

[143]  E. Fragopoulou,et al.  Effect of fast-food Mediterranean-type diet on type 2 diabetics and healthy human subjects' platelet aggregation. , 2006, Diabetes research and clinical practice.

[144]  D. Iliopoulos,et al.  In vivo antiatherogenic properties of olive oil and its constituent lipid classes in hyperlipidemic rabbits. , 2006, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[145]  Shi-hai Xia,et al.  Role of platelet-activating factor in pathogenesis of acute pancreatitis , 2006 .

[146]  A. Evangelou,et al.  Inhibition by cardiolipins of platelet-activating factor-induced rabbit platelet activation , 1993, Lipids.

[147]  Y. Naito,et al.  Role of platelet-activating factor (PAF) in superoxide production by human polymorphonuclear leukocytes , 1991, Lipids.

[148]  E. Fragopoulou,et al.  Characterization of Acetyl-CoA: Lyso-PAF Acetyltransferase of Human Mesangial Cells , 2005, Mediators of inflammation.

[149]  J. Travers,et al.  Ultraviolet B Radiation Generates Platelet-activating Factor-like Phospholipids underlying Cutaneous Damage* , 2005, Journal of Biological Chemistry.

[150]  C. O'neill The role of paf in embryo physiology. , 2005, Human reproduction update.

[151]  Subodh Kumar,et al.  Platelet activating factor improves the in vitro penetration of zona free hamster eggs by buffalo (Bubalus bubalis) spermatozoa. , 2005, Theriogenology.

[152]  P. Braquet,et al.  Inhibition of antigen-induced lung anaphylaxis in the guinea-pig by BN 52021 a new specific paf-acether receptor antagonist isolated from Ginkgo biloba , 2005, Agents and Actions.

[153]  J. Conard,et al.  Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin , 2005, Agents and Actions.

[154]  J. Benveniste Jacques Benveniste , 2004, BMJ : British Medical Journal.

[155]  B. Aggarwal,et al.  Nuclear factor-kappaB: a friend or a foe in cancer? , 2004, Biochemical pharmacology.

[156]  N. Bazan,et al.  Interplay among platelet‐activating factor, oxidative stress, and group I metabotropic glutamate receptors modulates neuronal survival , 2004, Journal of neuroscience research.

[157]  D. Lewis,et al.  Augmentation of Chemotherapy-Induced Cytokine Production by Expression of the Platelet-Activating Factor Receptor in a Human Epithelial Carcinoma Cell Line1 , 2004, The Journal of Immunology.

[158]  M. Mathonnet,et al.  Elevated plasma phospholipase A2 and platelet-activating factor acetylhydrolase activity in colorectal cancer. , 2004, Mediators of inflammation.

[159]  I. Izquierdo,et al.  A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis. , 2004, Journal of investigational allergology & clinical immunology.

[160]  Smaragdi Antonopoulou,et al.  Platelet activating factor — a molecular link between atherosclerosis theories , 2003 .

[161]  G. Baltas,et al.  Hydroxyl-platelet-activating factor exists in blood of healthy volunteers and periodontal patients. , 2003, Mediators of inflammation.

[162]  P. Halligan,et al.  Neuroprotection during cardiac surgery: a randomised trial of a platelet activating factor antagonist , 2003, Heart.

[163]  L. Kemény,et al.  Platelet-Activating Factor Antagonist WEB 2086 Inhibits Ultraviolet-B Radiation-Induced Dermatitis in the Human Skin , 2003, Skin Pharmacology and Physiology.

[164]  A. Tselepis,et al.  Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. , 2002, Atherosclerosis. Supplements.

[165]  J. Witztum,et al.  C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[166]  F. Gruber,et al.  Protective role of phospholipid oxidation products in endotoxin-induced tissue damage , 2002, Nature.

[167]  G. Zimmerman,et al.  Activation of vascular cells by PAF-like lipids in oxidized LDL. , 2002, Vascular pharmacology.

[168]  K. Shimizu,et al.  Novel agents combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI). , 2002, Bioorganic & medicinal chemistry letters.

[169]  P. Libby,et al.  Inflammation and Atherosclerosis , 2002, Circulation.

[170]  J. Eckman,et al.  Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor. , 2001, Pharmacological research.

[171]  D. Fatovich,et al.  Platelet-activating factor antagonism and streptokinase-induced hypotension in clinical acute myocardial infarction. , 2001, Clinical science.

[172]  I. Jantan,et al.  Inhibitory effects of xanthones on platelet activating factor receptor binding in vitro. , 2001, Journal of ethnopharmacology.

[173]  J. Heinecke,et al.  Mechanisms for oxidizing low-density lipoprotein. Insights from patterns of oxidation products in the artery wall and from mouse models of atherosclerosis. , 2001, Trends in cardiovascular medicine.

[174]  G. Zimmerman,et al.  Oxidized LDL contains inflammatory PAF-like phospholipids. , 2001, Trends in cardiovascular medicine.

[175]  H. Schaefers,et al.  Impact of PAF antagonist BN 52021 (Ginkolide B) on post-ischemic graft function in clinical lung transplantation. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[176]  J. Neoptolemos,et al.  Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis , 2001, Gut.

[177]  S Russo,et al.  PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. , 2000, The American journal of pathology.

[178]  J. Lysiak,et al.  Dithiolane analogs of lignans inhibit interferon-gamma and lipopolysaccharide-induced nitric oxide production in macrophages. , 2000, Acta pharmacologica Sinica.

[179]  G. Zimmerman,et al.  The Leukocyte Integrins* , 2000, The Journal of Biological Chemistry.

[180]  T. Nomikos,et al.  Separation of biologically active lipids from red wine. , 2000, Journal of agricultural and food chemistry.

[181]  J. Vincent,et al.  Phase II multicenter clinical study of the platelet‐activating factor receptor antagonist BB‐882 in the treatment of sepsis , 2000, Critical care medicine.

[182]  J. Simpson,et al.  A Double-Blind Placebo-Controlled Study of an Infusion of Lexipafant (Platelet-Activating Factor Receptor Antagonist) in Patients with Severe Sepsis , 2000, Antimicrobial Agents and Chemotherapy.

[183]  G. Camussi,et al.  Role of platelet-activating factor in cardiovascular pathophysiology. , 2000, Physiological reviews.

[184]  G. Zimmerman,et al.  Platelet-activating factor and related lipid mediators. , 2000, Annual review of biochemistry.

[185]  G. Ramsay,et al.  Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group. , 2000, Shock.

[186]  S. Ishii,et al.  Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. , 2000, Progress in lipid research.

[187]  P. Dentelli,et al.  Thrombopoietin stimulates endothelial cell motility and neoangiogenesis by a platelet-activating factor-dependent mechanism. , 1999, Circulation research.

[188]  D. Tew,et al.  Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. , 1999, The Biochemical journal.

[189]  F. Snyder The ether lipid trail: a historical perspective. , 1999, Biochimica et biophysica acta.

[190]  C. Hawkey,et al.  Lack of effectiveness of the platelet-activating factor antagonist SR27417A in patients with active ulcerative colitis: a randomized controlled trial. The Platelet Activating Factor Antagonist Study Group in Ulcerative Colitis. , 1998, Gastroenterology.

[191]  M. Schaller,et al.  Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group. , 1998, Critical care medicine.

[192]  A. Sapino,et al.  Potential angiogenic role of platelet-activating factor in human breast cancer. , 1998, The American journal of pathology.

[193]  P. Hilliquin,et al.  A double blind, placebo controlled study of a platelet activating factor antagonist in patients with rheumatoid arthritis. , 1998, The Journal of rheumatology.

[194]  V. Peinado,et al.  Effect of a platelet-activating factor (PAF) antagonist, SR 27417A, on PAF-induced gas exchange abnormalities in mild asthma. , 1998, The European respiratory journal.

[195]  Jung Joon Lee,et al.  Platelet-activating factor antagonistic activity and13C NMR assignment of pregomisin and chamigrenal fromSchisandra chinensis , 1997, Archives of pharmacal research.

[196]  J. Bian,et al.  Piperbetol, methylpiperbetol, piperol A and piperol B: a new series of highly specific PAF receptor antagonists from Piper betle. , 1997, Planta medica.

[197]  P. Barnes,et al.  Effects of a potent platelet-activating factor antagonist, SR27417A, on allergen-induced asthmatic responses. , 1997, American journal of respiratory and critical care medicine.

[198]  Y. Hirashima,et al.  Involvement of platelet-activating factor (PAF) in glutamate neurotoxicity in rat neuronal cultures , 1997, Brain Research.

[199]  V. I. Kulikov,et al.  Ether lipids and platelet-activating factor: evolution and cellular function. , 1997, Biochemistry. Biokhimiia.

[200]  Paul F. Smith,et al.  PLATELET-ACTIVATING FACTOR IN THE CNS , 1996, Progress in Neurobiology.

[201]  C. Semidalas,et al.  Platelet-activating factor (PAF) antagonists in foods : A study of lipids with PAF or anti-PAF-like activity in cow's milk and yogurt , 1996 .

[202]  A. Weyrich,et al.  Activated platelets signal chemokine synthesis by human monocytes. , 1996, The Journal of clinical investigation.

[203]  C. A. Demopoulos,et al.  A discovery trip to compounds with PAF-like activity. , 1996, Advances in experimental medicine and biology.

[204]  D. Argyropoulos,et al.  Biologically active lipids from S. scombrus. , 1996, Advances in experimental medicine and biology.

[205]  C. Iatrou,et al.  Blood cardiolipin in haemodialysis patients. Its implication in the biological action of platelet-activating factor. , 1996, The international journal of biochemistry & cell biology.

[206]  H. Bito,et al.  Platelet-activating factor receptor. , 2002, Journal of lipid mediators and cell signalling.

[207]  R. Dean,et al.  Human atherosclerotic plaque contains both oxidized lipids and relatively large amounts of alpha-tocopherol and ascorbate. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[208]  L. Formela,et al.  Randomized, double‐blind phase II trial of Lexipafant, a platelet‐activating factor antagonist, in human acute pancreatitis , 1995, The British journal of surgery.

[209]  M. Yamakido,et al.  Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma. , 1995, American journal of respiratory and critical care medicine.

[210]  D. Albert,et al.  Platelet activating factor antagonists. , 1995, Advances in pharmacology.

[211]  L. McManus,et al.  Lipid inhibitors of platelet-activating factor (PAF) in normal human plasma. , 1995, Journal of lipid mediators and cell signalling.

[212]  K. Chung,et al.  Effect of a novel potent platelet-activating factor antagonist, modipafant, in clinical asthma. , 1995, American journal of respiratory and critical care medicine.

[213]  G. Zimmerman,et al.  Anti-inflammatory properties of a platelet-activating factor acetylhydrolase , 1995, Nature.

[214]  P. Braquet,et al.  Platelet-activating factor antagonists , 1995, Clinical Reviews in Allergy.

[215]  Fred L. Snyder Metabolic processing of PAF , 1995, Clinical reviews in allergy.

[216]  P. Kerkhof,et al.  The effect of topical application of the platelet‐activating factor‐antagonist, Ro 24‐0238, in psoriasis vulgaris—a clinical and immunohistochemical study , 1994, Clinical and experimental dermatology.

[217]  K. Chung,et al.  Inhibitory effect of UK,74505, a potent and specific oral platelet activating factor (PAF) receptor antagonist, on airway and systemic responses to inhaled PAF in humans. , 1994, American journal of respiratory and critical care medicine.

[218]  Smaragdi Antonopoulou,et al.  Platelet-activating factor formation during oxidative modification of low-density lipoprotein when PAF-acetylhydrolase has been inactivated. , 1994, Biochimica et biophysica acta.

[219]  M. Triggiani,et al.  Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet-activating factor. , 1994, The Journal of clinical investigation.

[220]  P. Calverley,et al.  The effect of the orally active platelet-activating factor antagonist WEB 2086 in the treatment of asthma. , 1994, American journal of respiratory and critical care medicine.

[221]  C. Semidalas,et al.  PAF antagonists in foods: isolation and identification of PAF antagonists in honey and wax , 1994 .

[222]  A. Evangelou Platelet-activating factor (PAF): implications for coronary heart and vascular diseases. , 1994, Prostaglandins, leukotrienes, and essential fatty acids.

[223]  R. Mcclure,et al.  Effect of platelet-activating factor (PAF) on human spermatozoa-oocyte interactions. , 1993, Journal of reproduction and fertility.

[224]  M. Olson,et al.  Platelet-activating factor: receptors and signal transduction. , 1993, The Biochemical journal.

[225]  P. O'Byrne,et al.  Effect of a platelet activating factor antagonist, WEB 2086, on allergen induced asthmatic responses. , 1993, Thorax.

[226]  R. P. McManus,et al.  Tulopafant, a PAF receptor antagonist, increases capillary patency and prolongs survival in discordant cardiac xenotransplants. , 1993, Journal of lipid mediators.

[227]  F. Valone Quantifying platelet-activating factor in biologic systems. , 1993, The Journal of allergy and clinical immunology.

[228]  C. Semidalas,et al.  PAF antagonists in foods: isolation and identification of PAF antagonists in virgin olive oil , 1993 .

[229]  K. P. Hui,et al.  Effect of the platelet-activating factor antagonist UK-74,505 on the early and late response to allergen. , 1993, The American review of respiratory disease.

[230]  S. Kerwar,et al.  Analogues of platelet activating factor. 6. Mono- and bis-aryl phosphate antagonists of platelet activating factor. , 1992, Journal of medicinal chemistry.

[231]  H. Sarau,et al.  Platelet-activating factor stimulates phosphoinositide turnover in neurohybrid NCB-20 cells: involvement of pertussis toxin-sensitive guanine nucleotide-binding proteins and inhibition by protein kinase C. , 1992, Molecular pharmacology.

[232]  J. García-Rafanell,et al.  Effects of PAF‐antagonists in mouse ear oedema induced by several inflammatory agents , 1991, British journal of pharmacology.

[233]  D. Stafforini,et al.  Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates. , 1991, The Journal of biological chemistry.

[234]  K. Hsieh Effects of PAF antagonist, BN52021, on the PAF-, methacholine-, and allergen-induced bronchoconstriction in asthmatic children. , 1991, Chest.

[235]  F. Bussolino,et al.  Acetylcholine‐induced production of platelet‐activating factor by human fetal brain cells in culture , 1990, Journal of neuroscience research.

[236]  S. Morooka,et al.  Biological effect of orally active platelet-activating factor receptor antagonist SM-10661. , 1990, Molecular pharmacology.

[237]  Hwang Sb Specific receptors of platelet-activating factor, receptor heterogeneity, and signal transduction mechanisms. , 1990 .

[238]  H. Heuer,et al.  Use of WEB 2086 and WEB 2170 as platelet-activating factor antagonists. , 1990, Methods in enzymology.

[239]  S. Hwang Specific receptors of platelet-activating factor, receptor heterogeneity, and signal transduction mechanisms. , 1990, Journal of lipid mediators.

[240]  B. Minhas,et al.  Effects of platelet activating factor on mouse oocyte fertilization in vitro. , 1989, American journal of obstetrics and gynecology.

[241]  B. Spur,et al.  Occurrence of platelet-activating factor (PAF) and an endogenous inhibitor of platelet aggregation in diffuse cutaneous mastocytosis. , 1989, Clinical and experimental immunology.

[242]  M. Rouis,et al.  Platelet activating factor is a potent stimulant of the production of active oxygen species by human monocyte-derived macrophages. , 1988, Biochemical and biophysical research communications.

[243]  J. Arnout,et al.  EFFECTIVENESS AND TOLERABILITY OF CV-3988, A SELECTIVE PAF ANTAGONIST, AFTER INTRAVENOUS ADMINISTRATION TO MAN , 1988, Thrombosis and Haemostasis.

[244]  P. Braquet,et al.  Presence of specific binding sites for platelet-activating factor (PAF) in brain. , 1988, Biochemical and biophysical research communications.

[245]  Y. Imura,et al.  CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo. , 1987, The Journal of pharmacology and experimental therapeutics.

[246]  D. Stafforini,et al.  Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. , 1987, The Journal of biological chemistry.

[247]  A. Evangelou,et al.  Electrocardiographic alterations induced by AGEPC in Wistar rats in relation to its hypotensive and hematologic effects. , 1987, Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology.

[248]  B. Vargaftig,et al.  PAF-acether-induced synthesis of prostacyclin by human endothelial cells. , 1986, European journal of pharmacology.

[249]  J. Tomesch,et al.  Inhibition of PAF-induced systemic responses in the rat, guinea pig, dog and primate by the receptor antagonist SRI 63-441. , 1986, Thrombosis and haemostasis.

[250]  P. Braquet,et al.  Hemodynamic effects of PAF-acether. , 1986, Pharmacological research communications.

[251]  P. Braquet,et al.  Thrombus induction by endogenic paf-acether and its inhibition by Ginkgo Biloba extracts in the guinea pig. , 1986, Prostaglandins.

[252]  G. Camussi Potential role of platelet-activating factor in renal pathophysiology. , 1986, Kidney international.

[253]  K. Kubo,et al.  Effects of ONO-6240, a platelet-activating factor antagonist, on endotoxin shock in unanesthetized sheep. , 1986, Prostaglandins.

[254]  P. Braquet Proofs of involvement of PAF-acether in various immune disorders using BN 52021 (ginkgolide B): a powerful PAF-acether antagonist isolated from Ginkgo biloba L. , 1986, Advances in prostaglandin, thromboxane, and leukotriene research.

[255]  N. Andrikopoulos,et al.  Biological activity of lipids of pine pollen on platelet aggregation in correlation with the platelet activating factor. , 1986, Biochemistry International.

[256]  S. Hwang,et al.  trans-2,5-Bis-(3,4,5-trimethoxyphenyl)tetrahydrofuran. An orally active specific and competitive receptor antagonist of platelet activating factor. , 1985, The Journal of biological chemistry.

[257]  Kathy,et al.  BN 52021 and related compounds: A new series of highly specific PAF-acether receptor antagonists isolated from Ginkgo biloba L. , 1985 .

[258]  M. Record,et al.  Evidence that biosynthesis of platelet‐activating factor (paf‐acether) by human neutrophils occurs in an intracellular membrane , 1985, FEBS letters.

[259]  G. Zimmerman,et al.  Production of platelet-activating factor by human vascular endothelial cells: evidence for a requirement for specific agonists and modulation by prostacyclin. , 1985, Circulation.

[260]  X. Wang,et al.  Characterization of a platelet-activating factor receptor antagonist isolated from haifenteng (Piper futokadsura): specific inhibition of in vitro and in vivo platelet-activating factor-induced effects. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[261]  F. Valone Inhibition of binding of the platelet-activating factor AGEPC to platelets by the AGEPC analog rac-3-(N-n-octadecylcarbamoyloxy)-2-methoxypropyl 2-thiazolioethyl phosphate (CV-3988). , 1985, Biochemical and biophysical research communications.

[262]  R. Lenox,et al.  Platelet-activating factor-induced aggregation of human platelets specifically inhibited by triazolobenzodiazepines. , 1984, Science.

[263]  G. Zimmerman,et al.  Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[264]  C. Page,et al.  Platelet‐activating factor: a possible mediator of the dual response to allergen? , 1984, Clinical allergy.

[265]  Mahendra K. Jain,et al.  Effects of garlic extract and of three pure components isolated from it on human platelet aggregation, arachidonate metabolism, release reaction and platelet ultrastructure. , 1983, Thrombosis research.

[266]  H. Nomura,et al.  CV-3988 - a specific antagonist of platelet activating factor (PAF). , 1983, Life sciences.

[267]  J. V. Levy Calmodulin Antagonist W-7 Inhibits Aggregation of Human Platelets Induced by Platelet Activating Factor , 1983, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[268]  J. Palmer,et al.  Differential effects of platelet depletion on the physiologic alterations of IgE anaphylaxis and acetyl glyceryl ether phosphorylcholine infusion in the rabbit. , 1981, The American review of respiratory disease.

[269]  F. Snyder,et al.  Biosynthesis of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet activating factor and a hypotensive lipid) by cholinephosphotransferase in various rat tissues. , 1981, Biochimica et biophysica acta.

[270]  L. Douste-Blazy,et al.  Biosynthetic labelling of platelet activating factor from radioactive acetate by stimulated platelets , 1981, Nature.

[271]  F. Snyder,et al.  A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid). , 1981, The Journal of biological chemistry.

[272]  J. Benveniste,et al.  Release of 1-O-alkylglyceryl 3-phosphorylcholine, O-deacetyl platelet-activating factor, from leukocytes: chemical ionization mass spectrometry of phospholipids. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[273]  J. Palmer,et al.  Respiratory and circulatory alterations induced by acetyl glyceryl ether phosphorylcholine, a mediator of IgE anaphylaxis in the rabbit. , 1980, The American review of respiratory disease.

[274]  L. McManus,et al.  Complement localization and mediation of ischemic injury in baboon myocardium. , 1980, The Journal of clinical investigation.

[275]  F. Bussolino,et al.  Pharmacological modulation of platelet-activating factor (PAF) release from rabbit leucocytes. I. Role of cAMP. , 1980, Immunology.

[276]  J. Liehr,et al.  Identification of platelet activating factor isolated from rabbit basophils as acetyl glyceryl ether phosphorylcholine. , 1980, The Journal of biological chemistry.

[277]  L. McManus,et al.  Pathobiology of the intravenous infusion of acetyl glyceryl ether phosphorylcholine (AGEPC), a synthetic platelet-activating factor (PAF), in the rabbit. , 1980, Journal of immunology.

[278]  N. Cusack Platelet-activating factor , 1980, Nature.

[279]  F. Snyder,et al.  Antihypertensive activity of an alkyl ether analog of phosphatidylcholine. , 1979, Biochemical and biophysical research communications.

[280]  D. Hanahan,et al.  Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). , 1979, The Journal of biological chemistry.

[281]  D. Hanahan,et al.  Physicochemical and functional identity of rabbit platelet-activating factor (PAF) released in vivo during IgE anaphylaxis with PAF released in vitro from IgE sensitized basophils. , 1979, Journal of immunology.

[282]  B. Vargaftig,et al.  The role of platelet-activating factor in platelet aggregation , 1979, Nature.

[283]  J. Polonsky,et al.  Semi-synthèse et structure proposée du facteur activant les plaquettes (P.A.F.): PAF-acether, un alkyl ether analogue de la lysophosphatidylcholine. , 1979 .

[284]  P. Henson,et al.  Basophil-derived platelet-activating factor (PAF) as an in vivo mediator of acute allergic reactions: demonstration of specific desensitization of platelets to PAF during IgE-induced anaphylaxis in the rabbit. , 1977, Journal of immunology.

[285]  J. Benveniste,et al.  Structural analysis of purified platelet-activating factor by lipases , 1977, Nature.

[286]  J. Benveniste,et al.  Platelet-activating factor, a new mediator of anaphylaxis and immune complex deposition from rabbit and human basophils , 1974, Nature.

[287]  P. Henson,et al.  LEUKOCYTE-DEPENDENT HISTAMINE RELEASE FROM RABBIT PLATELETS THE ROLE OF IGE, BASOPHILS, AND A PLATELET-ACTIVATING FACTOR , 1972 .

[288]  A. G. Osler,et al.  Destruction of rabbit platelets in the allergic response of sensitized leukocytes. I. Demonstration of a fluid phase intermediate. , 1971, Journal of immunology.

[289]  A. J. Slotboom,et al.  Hydrolysis of phosphoglycerides by purified lipase preparations I. Substrate-, positional- and stereo-specificity , 1970 .

[290]  N. Zvaifler,et al.  Antigen Induced Histamine Release from Platelets of Rabbits Producing Homologous PGA Antibody. , 1966, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[291]  L. M. Deenen,et al.  Structural identification of isomeric lysolecithins , 1965 .